Degree Granting Department
David Merkler, Ph.D.
Randy Larsen, Ph.D.
Gloria Ferreira, Ph.D.
enzyme, prostate, inhibition, 4-hpr, kinetics
C-Terminal glycine-extended prohormones are enzymatically converted to á-amidated peptides, by peptidylglycine á-amidating monooxygenase (PAM). PAM is a bifunctional enzyme with two catalytic domains: peptidylglycine á-hydroxylating monooxygenase (PHM) and peptidylglycine peptidylglycineaminoglycolate lyase (PAL).
PAM has a significant role in the proliferation of androgen-independent prostate cancer. Thus, the inhibition of PAM could halt cancer growth. Hippurate and hippurate analogs were used as lead compounds for developing inhibitors for PAM. The hippurate analogs exhibiting the highest affinity to PAM (lowest inhibition constant) did inhibit the growth of human androgen-independent prostate cancer DU 145 cells.
Scholar Commons Citation
Chew, Geoffrey H., "Substrate-Based Inhibitors of Peptidylglycine á-Amidating Monooxygenase (PAM) as Anti-Proliferative Drugs for Cancer" (2003). Graduate Theses and Dissertations.